10 Best Immunotherapy Stocks to Buy Now
The global immunotherapy drugs market is rapidly expanding, with projections to grow from $240 billion in 2023 to $1.3 trillion by 2033.
No. | Hedge Fund | Shares | Value | Activity | % Port |
---|---|---|---|---|---|
1. | Fisher Asset Management Ken Fisher | 10,480,160 | $816,509,273 | +6% | 0.33% |
2. | GQG Partners Rajiv Jain | 5,475,142 | $426,568,337 | +83% | 0.66% |
3. | Soros Fund Management George Soros | 2,652,771 | $206,677,389 | +9% | 2.98% |
4. | D E Shaw D. E. Shaw | 1,591,455 | $123,990,259 | +4672% | 0.1% |
5. | 1,294,300 | $100,838,913 | -42% | 0.01% |
No. | Name | Shares | Value | % Port |
---|---|---|---|---|
1. | 49,444,180 | $3,330,065,523 | 0.62% | |
2. | 42,987,075 | $2,895,179,501 | 2.29% | |
3. | 34,782,762 | $2,342,366,533 | 0.52% | |
4. | 21,321,999 | $1,436,036,640 | 0.11% | |
5. | 17,732,542 | $1,194,286,722 | 0.89% |